Out-of-Specification (OOS)

Out-of-Specification (OOS) designates test results for pharmaceutical materials or products that fall outside established acceptance criteria defined in approved specifications, indicating potential quality failure requiring investigation and resolution before batch release. OOS results may arise from analytical errors, sampling issues, equipment malfunction, manufacturing deviations, or genuine product defects, managed through formal quality systems ensuring patient safety and regulatory compliance.

The biopharmaceutical industry manages OOS results through structured investigation processes aligned with GMP expectations. Initial assessments determine whether laboratory error or method issues contributed, followed by comprehensive root cause analysis examining manufacturing records, equipment logs, and environmental conditions. Confirmatory testing is tightly controlled, with retesting permitted only under justified circumstances. If OOS is confirmed, batches may be rejected, reprocessed, or subjected to additional evaluation. OOS trends may reveal systemic process weaknesses requiring corrective and preventive actions. Regulatory inspections frequently scrutinise OOS handling, with inadequate investigations considered serious compliance failures. As manufacturing becomes more data-driven through digital quality systems and real-time monitoring, OOS management continues evolving toward proactive detection and prevention.